Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of October 2021. The report serves as a transaction notification regarding a purchase of company securities by a Person Discharging Managerial Responsibilities (PDMR).
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It is strictly a disclosure of a specific insider transaction.
| Metric | Value |
|---|---|
| Transaction Type | Acquisition of notional ADSs |
| Instrument | American Depositary Shares (ADSs) |
| Price per ADS | $39.77 |
| Volume | 1,257.428 ADSs |
| Transaction Date | October 22, 2021 |
| Exchange | New York Stock Exchange (XNYS) |
Material Changes
No material changes to the company's financial position or operations are reported in this filing. The document details a single transaction within an executive savings plan and does not compare performance against prior periods.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or discussion of contingencies. The transaction was executed within Dr. H. Barron's GSK Executive Supplemental Savings Plan account.
Key Facts for Investor Verification
- Insider Identity: The transaction was executed by Dr. H. Barron, Chief Scientific Officer and President, R&D.
- Transaction Nature: This was an acquisition of notional ADSs, not a direct open-market purchase of physical shares.
- Valuation: The transaction occurred at a price of $39.77 per ADS on October 22, 2021.
- Scope: This filing does not contain quarterly or annual financial results; investors should refer to Form 20-F for comprehensive financial data.